Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of TS23 in Intermediate-Risk Acute Pulmonary Embolism
NCT05408546Phase 2Active, not recruiting
- Sponsor
- Translational Sciences, Inc.
- Start
- May 2023
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TS23 in pulmonary embolism (PE), sponsored by Translational Sciences, Inc.. Started May 2023; status: active, not recruiting.
02
Drugs
TS23
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT05408546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05408546.